Comparison of Plazomicin MIC Test Strip and Broth Microdilution MIC Results for 125 Enterobacteriaceae
/L. Koeth, J. DiFranco-Fisher, A.W. Serio;
Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States
/M CASTANHEIRA, JM STREIT, AW SERIO, KM KRAUSE, RK FLAMM
Microbiological Outcomes With Plazomicin Versus Meropenem in Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in the EPIC Study
/Tiffany R. Keepers, Deborah S. Cebrik, Daniel J. Cloutier, Allison S. Komirenko, Lynn E. Connolly, Kevin M. Krause
Microbiological Outcomes With Plazomicin Versus Colistin in Patients With Bloodstream Infections Caused by Carbapenem-resistant Enterobacteriaceae in the CARE Study
/Alisa W. Serio; Kevin M. Krause; Irene Galani; Ana Cristina Gales; Adrian Jubb; Lynn E. Connolly; Alex Smith
Mass Balance, Metabolism, and Excretion of [14C]-Plazomicin in Healthy Human Subjects
/Taylor Choi; Julie D. Seroogy; Mitesh Sanghvi; Shyeilla V. Dhuria
In vitro activity of plazomicin, a next-generation aminoglycoside, against carbapenemase-producing Klebsiella pneumoniae
/Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed, Daniel D. Rhoads, Kristine M. Hujer, Andrea M. Hujer, Susan D. Rudin, T. Nicholas Domitrovic, Lynn Connolly, Kevin M. Krause, Sandra S. Richter, David van Duin, Barry N. Kreiswirth, Robert A. Bonomo
Pharmacokinetics/Pharmacodynamics (PK/PD) of Plazomicin (PLZ) against Carbapenem- Resistant Enterobacteriaceae (CRE) in Neutropenic Murine Thigh Infection and Pneumonia Models
/Arnold Louie, M.D., Weiguo Liu, M.D., Jocelyn Nole, B.S., Jenny Myrick, B.S., Michael Maynard, B.S., David Brown, B.S., M.B.A., Brandon Duncanson, B.S., M.S., Kevin Krause, BS, MBA, G. L. Drusano, M.D.
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2 and 3 Studies
/M. Trang, J.D. Seroogy, S.A. VanWart, S.M. Bhavnani, A. Kim, P.G. Ambrose, C.M. Rubino
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Plazomicin Dose Selection and Recommendations for Interpretive Criteria for In Vitro Susceptibility Testing for Enterobacteriaceae
/S.M. Bhavnani, J.P. Hammel, M. Trang, A. Kim, K.M. Krause, M. Castanheira, C.M. Rubino, P.G. Ambrose, G.L. Drusano
Assessment of AUC-Based Therapeutic Drug Management Algorithms for Plazomicin Therapy in Patients with Bloodstream Infection
/M. Trang, C.M. Rubino, J.P. Hammel, J.D. Seroogy, A. Kim, A. Forrest, S.M. Bhavnani
Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide
/M CASTANHEIRA, JM STREIT, SJR ARENDS, RK FLAMM
A Multi-Site Study Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Plazomicin using Non- Fastidious Gram-Negative Organisms
/N.M. Holliday, C.C. Knapp, S.B. Killian, S.M. Andrus, T.C. Lewis, J.M. Lindley, J.M. Streit, R.K. Flamm, B.J. Olson, T.R. Fritsche, J.W. Decousser, E. Scopes, A.M. Leonte, A.W. Serio
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Plazomicin Dose Selection and Recommendations for Interpretive Criteria for In Vitro Susceptibility Testing for Enterobacteriaceae
/S.M. Bhavnani, J.P. Hammel, M.Trang, A. Kim, K.M. Krause, M. Castanheira, C.M. Rubino, P.G. Ambrose, G.L. Drusano
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2 and 3 Studies
/M. Trang, J. Seroogy, S.A. Van Wart, S.M. Bhavnani, A. Kim, P.G. Ambrose, C.M. Rubino
In vitro activity of plazomicin against blood isolates of Klebsiella spp blood isolates
/Ümran Liste, Şeyma Nigiz, Aslı Çakar, Belgin Altun, Banu Sancak, Deniz Gür.
Plazomicin Activity Against Enterobacteriaceae Collected from Europe, Latin America, and Asia-Pacific during 2016, Including Those with Aminoglycoside and Beta-Lactam Resistance Mechanisms
/M Castanheira, RE Mendes, TB Doyle, JM Streit, AW Serio, KM Krause, RK Flamm
Plazomicin is Associated with Fewer Post-Baseline Infectious Complications Compared with Colistin in Patients with Serious Infections due to Carbapenem-Resistant Enterobacteriaceae
/Konstantinos Pontikis; Anna Skiada; Alisa W. Serio; Alex Smith; Lynn E. Connolly
Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI): An Analysis by Complicating Factor in the EPIC Study
/Michal Nowicki; Daniel J. Cloutier; Allison S. Komirenko; Deborah S. Cebrik; Lynn E. Connolly; George D. Radavoi; Viorel Jinga
Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
/J.McKinnell, L.Connolly, R.Pushkin, A.Jubb, B.O'Keeffe, A.Serio, A.Smith, J.Gall, V.Riddle, K.Krause, J.Pogue
Poster abstract #1853, Session: Clinical Study with New Antibiotics and Antifungals